SCHEMBL21640928

SCHEMBL21640928

CCC(=O)NC1CN(C(c2ccccc2)c2ccccc2)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 1/20 0.50
MTNR1A P48039 4/20 0.49
MTNR1B P49286 4/20 0.49
OPRD1 P41143 1/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C19 P33261 2/20 0.46
HPGD P15428 1/20 0.46
RAB9A P51151 1/20 0.46
CNR1 P21554 2/20 0.45
CNR2 P34972 2/20 0.45
HTT P42858 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
MAPT P10636 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ALDH1A1 P00352 1/20 0.44
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
CYP1A2 P05177 1/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21640667 0.85 CYP3A4 (0.52) SLC6A9OPRD1CYP3A4CYP2C19HPGD
SCHEMBL377735 0.83 KMT2A (0.51) SLC6A9MTNR1AMTNR1BOPRD1CYP3A4
SCHEMBL4793162 0.83 NPSR1 (0.50) SLC6A9HPGDCNR1CNR2HTT
SCHEMBL21641014 0.82 MAPT (0.56) SLC6A9CYP3A4CYP2C19HPGDRAB9A
SCHEMBL27717458 0.82 CACNA1A (0.49) SLC6A9OPRD1CNR1CNR2HTT
SCHEMBL27717381 0.81 SLC6A9 (0.48) SLC6A9OPRD1CYP3A4CYP2C19CNR1
SCHEMBL13889298 0.81 SLC6A9 (0.51) SLC6A9CNR1CNR2HTTNPSR1
SCHEMBL1744817 0.78 NPSR1 (0.49) SLC6A9HPGDCNR1CNR2HTT
SCHEMBL5461890 0.77 ALDH1A1 (0.51) SLC6A9OPRD1CNR1CNR2ALDH1A1
SCHEMBL2793927 0.76 KMT2A (0.49) L3MBTL1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3604305-B1 NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF WAKUNAGA PHARMA CO LTD (JP) 2024-08-28 EP disclosed
CN-110520422-B Novel pyridonecarboxylic acid derivative or salt thereof 涌永制药株式会社 2023-09-05 CN disclosed
US-11286255-B2 Pyridone carboxylic acid derivative or salt thereof WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2022-03-29 US disclosed
US-20200062752-A1 NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2020-02-27 US disclosed
EP-3604305-A1 NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF Wakunaga Pharmaceutical Co., Ltd. (JP) 2020-02-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062752-A1 NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF RAB10, HDAC10, NEK10 SLC6A9 2277/4885MTNR1A 3500/4885MTNR1B 3941/4885
US-11286255-B2 Pyridone carboxylic acid derivative or salt thereof RARA, RAB10, RABL6 SLC6A9 2300/4885MTNR1A 3105/4885MTNR1B 3543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.